Calcium channel blockers not linked to breast cancer risk

Analysis of data on 50,757 women conflicts with previous research that suggested calcium channel blockers increase breast cancer risk

Woman taking tablet

A study published in 2013 showed that women taking calcium channel blockers for at least ten years had a two-fold increased risk of breast cancer[1]

To explore this association prospectively, US researchers analysed data on 50,757 women from a study that has followed the sisters of women with breast cancer since 2003. 

Over a median follow-up of 5.3 years, the risk of developing breast cancer was the same for long-term users of calcium channel blockers and women who did not take them. The rate of long-term calcium channel blocker use was identical (1.3%) among women who did and did not develop cancer. 

Reporting in Breast Cancer Research (online, 5 July 2016)[2]
, the team says their findings do not support previous reports suggesting an increased breast cancer risk, concerns over which could lead women to receive less effective hypertension treatment.


[1] Li CI, Daling JR, Tang MT, Haugen KL et al. Use of antihypertensive medications and breast cancer risk among women aged 55 to 74 years. JAMA Intern Med 2013;1731629–37. doi: 10.1001/jamainternmed.2013.9071

[2] Wilson LE, D’Aloisio AA, Sandler DP et al. Long-term use of calcium channel blocking drugs and breast cancer risk in a prospective cohort of US and Puerto Rican women. Breast Cancer Research 2016;18:61. doi: 10.1186/s13058-016-0720-6

Last updated
The Pharmaceutical Journal, Calcium channel blockers not linked to breast cancer risk;Online:DOI:10.1211/PJ.2016.20201470

You may also be interested in